41 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
experience; R&D staff with depth of neuroscience drug development expertise Experienced Management & Scientific Teams Targeting multibillion dollar diseases … Caggiano, MD, PhD CMO and Head of R&D acaggiano@cogrx.com John Doyle Chief Financial Officer jdoyle@cogrx.com
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
in mid 2024
Thank You Tony Caggiano, MD, PhD CMO and Head of R&D 914 - 221 - 6730 acaggiano@cogrx.com Lisa Ricciardi President & CEO 917 - 658 - 5789
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
engagement Next Steps: Preparations for Phase 3 & Commercialization
Thank You Tony Caggiano, MD, PhD CMO and Head of R&D 914-221-6730 acaggiano
8-K
EX-99.1
j8dy8tnqiwc
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.2
6xdmv76izxgyrpu3
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
6fciykg o0oacbz6
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
z4bi4roz02n8jo6bey
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-99.1
7b3pj9abkh7 2gg3
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-99.1
ni519f9k8yz71s5uhk
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
l8zc9m9
16 Jun 22
Regulation FD Disclosure
7:08am
DEF 14A
ah48ik h5aomhzpn0j7h
25 Apr 22
Definitive proxy
5:28pm
10-K
tbe ra7xz
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
cc2h61b
30 Mar 22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides
7:29am
8-K
EX-99.1
n5wbase
15 Mar 22
Regulation FD Disclosure
9:32am
8-K
EX-99.1
39py22k6pyx1
18 Nov 21
Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
8:30am
S-1
EX-10.28
x4cs33u jsmwd9pfr
19 Jul 21
IPO registration
7:02am
S-1
EX-10.31
5p14ah8 lx7lc4r7m
19 Jul 21
IPO registration
7:02am